Inhibiting transforming growth factor .beta. to prevent accumulation of extracellular matrix
CA 2124591 A1 · Owner: University Of Utah (The) · Inventors: Ruoslahti, Erkki I.; Border, Wayne A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides a method for treating or arresting the progress of pathologies characterized by an accumulation of extracellular matrix components by providing an agent to suppress the activity of transforming growth factor .beta. (TGF-.beta.) a peptide growth factor which is anabolic and leads to fibrosis and angiogenesis. Pathologies which can be so treated include the various fibrotic diseases such as fibrotic cancer fibrosis of the, lungs, arteriosclerosis post myocardial infarction, cardiac, fibrosis post-angioplasty restenosis, renal interstitial fibrosis scarring and diabetic nephropathy. The present invention further provides methods for treating diabetes and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed December 4, 1992. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended December 4, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by December 4, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.